Physician profile
Keith Morris
NPI 1841281334
$1,073.48
in general payments reported to CMS, 2019-2025
16 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $12.69 · 2021: $144 · 2023: $116 · 2024: $463 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $751 · Education: $84.00 · Gift: $81.81.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $750.67 |
| Education | $84.00 |
| Gift | $81.81 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $397.64 | 2020-2025 | |
| Phathom Pharmaceuticals, INC. | $124.17 | 2024-2025 | Voquezna |
| Janssen Biotech, INC. | $109.14 | 2025 | Tremfya |
| Braintree Laboratories, INC. | $81.81 | 2023 | Sutab |
| Pfizer INC. | $79.84 | 2025 | |
| Genzyme Corporation | $40.75 | 2021 | |
| Lilly USA, LLC | $37.14 | 2024-2025 | Omvoh |
| Micro-Tech Endoscopy USA, INC. | $35.57 | 2024 | Snares |
| Redhill Biopharma INC. | $33.91 | 2023 | Talicia |
| Fujifilm Healthcare Americas Corporation | $32.69 | 2024 | Fujifilm |
| Takeda Pharmaceuticals U.S.A., INC. | $32.46 | 2021-2024 | Gattex |
| Amgen INC. | $26.59 | 2021 | |
| Ardelyx, INC. | $25.23 | 2025 | Ibsrela |
| Vantage Technology LLC | $16.54 | 2025 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Keith Morris listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.